N/A N=28 Hyper-Arousal in Chronic Primary Insomnia
Chronic Insomnia
Primary: Sympathetic Baroreflex Sensitivity (BRS) Unit — -2.1; -4.3 bursts per 100 heart beats per mm Hg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=211 Sequenced Therapies for Comorbid and Primary Insomnias
Insomnia Comorbid to Psychiatric Disorder · Primary Insomnia
Primary: Percent of Participants Who Met Remission as Measured by the Insomnia Severity Index — 40.00; 34.94; 37.04; 48.15 percent remitted
N/A N=45 A High Density EEG Comparison of Sleep Patterns in Insomnia
Primary Insomnia
Primary: EEG Power During Sleep — 1.40; 1.17 μV^2/Hz — p=0.2791
Phase 3 N=707 Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
Primary Insomnia
Primary: Change From Baseline to Day 1&2 in Wake After Sleep Onset (WASO) — 85.0; 86.6; 92.3; 76.5 minutes — p=<0.0001
N/A N=30 Chronic Insomnia and CSF Markers of Dementia
Insomnia Chronic
Primary: CSF Markers Related to Dementia — 4332.1; 4824.0; 393.2; 419.4 picograms per milliliter
N/A N=28 The Psychoneuroimmunology of Insomnia
Primary Insomnia
Primary: Positive Antibody Response — 7; 7 participants
Phase 4 N=69 Characteristics of Sleep Patterns in Young Adults With and Without Insomnia
Sleep Disorders
Primary: Change in Pittsburgh Sleep Quality Index — -0.86; -3.15; -3.32 difference score of PSQI total
Phase 2 N=34 Chamomile for Chronic Primary Insomnia
Primary Insomnia · Chronic Insomnia
Primary: Change From Baseline of Chamomile Extract on Measures of Sleep at Day 28. — 83.3; 77.5 percentage of time asleep — p=0.21
N/A N=154 Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Menopause
Primary: Diary Based Sleepiness — 5.01; 5.13; 4.87; 4.72 score on a scale
Phase 3 N=30 Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study
Chronic Insomnia · Primary Insomnia
Primary: Pittsburgh Sleep Quality Index (PSQI) — 7.7; 9.2; 7.0; 8.2 units on a scale
Phase 3 N=460 A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)
Sleep Initiation and Maintenance Disorders · Mental Disorders · Dyssomnias
Primary: Change From Baseline in Total Sleep Time (TST) - 6-Month Treatment Period — 65.9; 19.3 minutes — p=<0.0001
Phase 2 N=137 Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients
Primary Insomnia
Primary: Latency to Persistent Sleep — -22.7; -39.1; -37.5 minutes
Phase 4 N=6 Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder
Post-traumatic Stress Disorder · Insomnia
Primary: Recruitment Rates — 1.03 participants enrolled per month
N/A N=188 Sleep Without Insomnia or The Use of Chronic Hypnotics
Sleep Initiation and Maintenance Disorders
Primary: Rates of Hypnotic Discontinuation — 64; 52 Participants — p=.039
Phase 3 N=789 Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients
Primary Insomnia
Primary: The Change From Baseline in Subjective Sleep Latency. — -19.1; -1.7 minutes — p=<0.05
N/A N=245 The RESTING Insomnia Study: Randomized Controlled Study on Effectiveness of Stepped-Care Sleep Therapy
Insomnia
Primary: Insomnia Severity Index (ISI) — 15.9; 15.4; 12.7; 11.6 score on a scale — p=0.001
N/A N=21 Treatment of Insomnia Secondary to Chronic Pain
Insomnia · Pain
Primary: Insomnia Severity — 6.0; 12.8; 4.4; 13.0 units on a scale — p=0.010
Phase 2 N=118 Internet-based Treatment for Chronic Insomnia
Insomnia · Insomnia Disorder
Primary: Sleep Quality — 1.77; 2.18 0-4 scale of sleep quality
Phase 2 N=112 Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
Chronic Primary Insomnia
Primary: Mean Wake Time After Sleep Onset (WASO) — 109.1; 98.7; 90.0; 77.7 minutes — p=0.0018
Phase 2 N=42 Effectiveness of BBT-I and Zopiclone for Chronic Insomnia
Insomnia Chronic
Primary: Insomnia Severity Index — 18.6; 18.9; 13.1; 14.0 units on a scale
N/A N=23 Transcranial Magnetic Stimulation for Treatment of Insomnia
Insomnia
Primary: Pittsburgh Sleep Quality Index ( PSQI) — 12.50; 11.70; 10.37; 9.50 score on a scale
N/A N=189 Insomnia Self-Management in Heart Failure
Cardiac Failure · Heart Failure · Congestive Heart Failure
Primary: Change in Insomnia Severity — -6.60; -3.46 score on a scale — p=0.0002
Phase 4 N=115 Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia
Insomnia · Insomnia Chronic
Primary: Treatment Response (Phase 1) — 94 Participants
Phase 4 N=41 Suvorexant and Trauma Related Insomnia
Insomnia · Posttraumatic Stress Disorder
Primary: Change in Insomnia Severity Index Score From Baseline. — 6.8; 8.6 units on a scale — p=<.05
N/A N=149 Insomnia Treatment for Women Veterans
Insomnia
Primary: Number of Participants Completing 5 Behavioral Treatment Sessions — 63; 70 Participants — p==.120
N/A N=56 Insomnia Treatment and Problems (the iTAP Study)
Insomnia · Alcohol; Harmful Use
Primary: Insomnia Severity — 6.86; 10.84; 6.58; 9.32 units on scale, Insomnia Severity Index
N/A N=63 Implementation of Brief Insomnia Treatments - Clinical Trial
Chronic Insomnia
Primary: Insomnia Severity Index (ISI) — 9.6; 11.0 score on a scale — p=<0.05
Phase 3 N=72 A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)
Primary Insomnia
Primary: Latency To Persistent Sleep (LPS) — 37.5; 24.4; 20.9; 12.8 Minutes
N/A N=100 Prescription Digital Therapeutic for the Treatment of Insomnia
Insomnia Chronic
Primary: Change in Insomnia Severity
Phase 2 N=326 Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)
Primary Insomnia
Primary: Sleep Efficiency (SE) on Night 1 and After 4 Weeks of Treatment — 74.8; 83.3; 84.8; 85.6 percentage of time in bed spent sleeping — p=<0.001